Our September 2019 edition launches!

Our September edition is now ready to read online.

Like Comment

The September issue includes partnering companies focused on immuno-oncology, and antibodies among others, showcasing their developments. 

The editorial features cover the success of monoclonal antibodies, the search for immuno-oncology checkpoint inhibitor partners and how to negotiate a biopharma term sheet.  

We also launch the first of our BioPharma Thought Leader articles, in which we hear from the CEO of Lonza.

Read the full issue here.

Go to the profile of Raveena Bhambra

Raveena Bhambra

Editor, BioPharma Dealmakers , Nature Research

Hello all, I am the Editor of BioPharma Dealmakers, a quarterly publication that assists companies in identifying potential partners in the pharmaceutical and biotechnology industry and appears in both Nature Biotechnology and Nature Reviews Drug Discovery. I am very passionate about the biopharma industry and have over 15 years of experience of working in the field, specifically in dealmaking, partnering and licensing. In my previous roles I have conducted partner searches identifying both products/technologies and partners for clients, and have edited and written dealmaking-focused reports.

No comments yet.